Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) EPS (Basic) (2016 - 2025)

Zevra Therapeutics' EPS (Basic) history spans 11 years, with the latest figure at $0.2 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 128.99% year-over-year to $0.2; the TTM value through Dec 2025 reached $1.37, up 160.62%, while the annual FY2025 figure was $1.4, 161.4% up from the prior year.
  • EPS (Basic) reached $0.2 in Q4 2025 per ZVRA's latest filing, up from -$0.01 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $1.24 in Q2 2025 to a low of -$2.49 in Q1 2021.
  • Average EPS (Basic) over 5 years is -$0.35, with a median of -$0.34 recorded in 2023.
  • Peak YoY movement for EPS (Basic): plummeted 2160.0% in 2022, then skyrocketed 358.33% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at $0.05 in 2021, then tumbled by 2160.0% to -$1.03 in 2022, then soared by 47.57% to -$0.54 in 2023, then fell by 27.78% to -$0.69 in 2024, then surged by 128.99% to $0.2 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's EPS (Basic) are $0.2 (Q4 2025), -$0.01 (Q3 2025), and $1.24 (Q2 2025).